Mass Spectrometer Market Segmentation:
Product Type Segment Analysis
The hybrid segment is anticipated to garner the largest share of 32.7% in the market during the forecast timeline. Its superior analytical capabilities and precision medicine investments are the key factors propelling the dominance of this subtype. The hybrid systems are a combination of high mass accuracy (sub-ppm) with rapid scanning, which is highly essential for multi-omics research. Besides, Thermo Fisher’s Orbitrap Fusion witnessed a 20.8% enhanced adoption in 2023, owing to the heightened pharmaceutical demand.
Application Segment Analysis
The pharmaceutical & biotech segment is projected to grow at a considerable rate, with a share of 25.4% in the market by the end of 2034. The regulatory mandates for drugs and biologics & and biosimilars boom are reinforcing the segment’s growth in this sector. Over 82.4% of top-selling drugs are biologics, such as Keytruda and Humira necessitate mass spectrometry for post-translational modification analysis. Furthermore, Agilent’s Q-TOF systems are currently utilized in 90.5% of biopharmaceutical labs for intact protein analysis, thus a wider segment scope.
Our in-depth analysis of the mass spectrometer market includes the following segments:
|
Segment |
Subsegments |
|
Product Type |
|
|
Technology |
|
|
Application |
|
|
End user |
|
